{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:35:46Z","timestamp":1790994946851,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institute for Psychobiology in Israel","award":["159-14-15"],"award-info":[{"award-number":["159-14-15"]}]},{"DOI":"10.13039\/100001203","name":"Kessler Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001203","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Europacific Medical"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physiology & Behavior"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.physbeh.2018.12.019","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T12:49:04Z","timestamp":1545050944000},"page":"59-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Effects of cannabidiol in males and females in two different rat models of depression"],"prefix":"10.1016","volume":"201","author":[{"given":"Liat","family":"Shbiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hen-Shoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Hazut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Rapps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Zalsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Mechoulam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Shoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.physbeh.2018.12.019_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013"},{"issue":"2","key":"10.1016\/j.physbeh.2018.12.019_bb0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","article-title":"Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats","volume":"199","author":"Campos","year":"2008","journal-title":"Psychopharmacology"},{"issue":"1607","key":"10.1016\/j.physbeh.2018.12.019_bb0015","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Phil. Trans. R. Soc. A"},{"key":"10.1016\/j.physbeh.2018.12.019_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ypmed.2017.07.008","article-title":"Cannabis use, attitudes, and legal status in the U.S.: a review","volume":"104","author":"Carliner","year":"2017","journal-title":"Prev. Med."},{"issue":"2","key":"10.1016\/j.physbeh.2018.12.019_bb0025","first-page":"16","article-title":"Real-world data on SSRI antidepressant side effects","volume":"6","author":"Cascade","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"issue":"1","key":"10.1016\/j.physbeh.2018.12.019_bb0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/alcalc\/agh110","article-title":"The endocannabinoid system: physiology and pharmacology","volume":"40","author":"De Fonseca","year":"2005","journal-title":"Alcohol Alcohol."},{"issue":"12","key":"10.1016\/j.physbeh.2018.12.019_bb0035","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-2236(98)01283-1","article-title":"Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action","volume":"21","author":"Di Marzo","year":"1998","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.physbeh.2018.12.019_bb0040","series-title":"Handbook of Cannabis and Related Pathologies","first-page":"795","article-title":"Chapter 82: Cannabidiol for the treatment of epilepsy: an overview of possible mechanisms of action and preclinical and human studies","author":"dos Santos","year":"2017"},{"issue":"4","key":"10.1016\/j.physbeh.2018.12.019_bb0045","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of \u0394 9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.physbeh.2018.12.019_bb0050","article-title":"The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: an integrative review of evidence, mechanisms, and clinical implications","author":"Fornaro","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"51","key":"10.1016\/j.physbeh.2018.12.019_bb0055","doi-asserted-by":"crossref","first-page":"18620","DOI":"10.1073\/pnas.0509591102","article-title":"Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis","volume":"102","author":"Gobbi","year":"2005","journal-title":"PNAS (USA)"},{"issue":"4","key":"10.1016\/j.physbeh.2018.12.019_bb0060","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.neuropharm.2006.11.005","article-title":"Repeated treatment with cannabidiol but not \u0394 9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance","volume":"52","author":"Hayakawa","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.physbeh.2018.12.019_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2018.05.027","article-title":"Acute oral Cannabidiolic Acid Methyl Ester reduces depression-like behavior in two genetic animal models of depression","volume":"351","author":"Hen-Shoval","year":"2018","journal-title":"Behav. Brain Res."},{"issue":"5\u20136","key":"10.1016\/j.physbeh.2018.12.019_bb0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00008877-200509000-00006","article-title":"Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?","volume":"16","author":"Hill","year":"2005","journal-title":"Behav. Pharmacol."},{"issue":"6","key":"10.1016\/j.physbeh.2018.12.019_bb0075","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.euroneuro.2005.03.003","article-title":"Pharmacological enhancement of cannabinoid CB 1 receptor activity elicits an antidepressant-like response in the rat forced swim test","volume":"15","author":"Hill","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.physbeh.2018.12.019_bb0080","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1038\/sj.npp.1301092","article-title":"Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic\u2013pituitary\u2013adrenal axis","volume":"31","author":"Hill","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.physbeh.2018.12.019_bb0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","article-title":"A systematic review of the antipsychotic properties of cannabidiol in humans","volume":"162","author":"Iseger","year":"2015","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.physbeh.2018.12.019_bb0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","article-title":"Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on \u03b2-amyloid-induced toxicity in PC12 cells","volume":"89","author":"Iuvone","year":"2004","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.physbeh.2018.12.019_bb0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.physbeh.2018.12.019_bb0100","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.neuropharm.2015.03.016","article-title":"Forced swim test: what about females","volume":"99","author":"Kokras","year":"2015","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.physbeh.2018.12.019_bb0105","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"20","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.physbeh.2018.12.019_bb0110","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/0269881108099956","article-title":"That warm fuzzy feeling: brain serotonergic neurons and the regulation of emotion","volume":"23","author":"Lowry","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.physbeh.2018.12.019_bb0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pneurobio.2009.03.003","article-title":"Two different putative genetic animal models of childhood depression\u2014a review","volume":"88","author":"Malkesman","year":"2009","journal-title":"Prog. Neurobiol."},{"issue":"5","key":"10.1016\/j.physbeh.2018.12.019_bb0120","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.phrs.2007.09.003","article-title":"Enhancement of endocannabinoid signaling and the pharmacotherapy of depression","volume":"56","author":"Mangieri","year":"2007","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.physbeh.2018.12.019_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/can.2017.0034","article-title":"Chronic adolescent \u03949-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment","volume":"2","author":"Murphy","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.physbeh.2018.12.019_bb0130","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.physbeh.2018.12.019_bb0135","series-title":"Psychiatric Disorders. Methods in Molecular Biology (Methods and Protocols)","first-page":"125","article-title":"Modeling depression in animal models","volume":"vol. 829","author":"Overstreet","year":"2012"},{"issue":"4","key":"10.1016\/j.physbeh.2018.12.019_bb0140","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neubiorev.2005.03.015","article-title":"The Flinders Sensitive Line rat: a selectively bred putative animal model of depression","volume":"29","author":"Overstreet","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1\u20132","key":"10.1016\/j.physbeh.2018.12.019_bb0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10681-004-4756-9","article-title":"Pharmacological and therapeutic targets for \u03949 tetrahydrocannabinol and cannabidiol","volume":"140","author":"Pertwee","year":"2004","journal-title":"Euphytica"},{"issue":"5","key":"10.1016\/j.physbeh.2018.12.019_bb0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000318293","article-title":"Efficacy and effectiveness of antidepressants: current status of research","volume":"79","author":"Pigott","year":"2010","journal-title":"Psychother. Psychosom."},{"issue":"6","key":"10.1016\/j.physbeh.2018.12.019_bb0155","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0165-6147(00)01482-6","article-title":"The endocannabinoid system as a target for therapeutic drugs","volume":"21","author":"Piomelli","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.physbeh.2018.12.019_bb0160","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Th\u00e9r."},{"issue":"6","key":"10.1016\/j.physbeh.2018.12.019_bb0165","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0031-9384(93)90351-F","article-title":"Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression","volume":"54","author":"Pucilowski","year":"1993","journal-title":"Physiol. Behav."},{"issue":"2","key":"10.1016\/j.physbeh.2018.12.019_bb0170","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbr.2006.05.016","article-title":"Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats","volume":"172","author":"Resstel","year":"2006","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.physbeh.2018.12.019_bb0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1476-5381.2008.00046.x","article-title":"5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats","volume":"156","author":"Resstel","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.physbeh.2018.12.019_bb0180","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1601-5215.2011.00579.x","article-title":"Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala","volume":"23","author":"R\u00e9us","year":"2011","journal-title":"Acta Neuropsychiatrica"},{"issue":"7","key":"10.1016\/j.physbeh.2018.12.019_bb0185","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","article-title":"Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects","volume":"163","author":"Russo","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.physbeh.2018.12.019_bb0190","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"issue":"18","key":"10.1016\/j.physbeh.2018.12.019_bb0195","first-page":"30116","article-title":"Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels","volume":"S0278-5846","author":"Sales","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.physbeh.2018.12.019_bb0200","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","article-title":"Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-possible involvement of 5-HT1A and CB1 receptors","volume":"303","author":"Sartim","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.physbeh.2018.12.019_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000443890","article-title":"Pro-hedonic effect of cannabidiol in a rat model for depression","volume":"73","author":"Shoval","year":"2016","journal-title":"Neuropsychobiology"},{"issue":"1","key":"10.1016\/j.physbeh.2018.12.019_bb0210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2007.09.008","article-title":"Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice","volume":"33","author":"Steiner","year":"2008","journal-title":"Psychoneuroendocrinology"},{"issue":"10","key":"10.1016\/j.physbeh.2018.12.019_bb0215","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.tips.2006.08.006","article-title":"Role of the endocannabinoid system in depression and suicide","volume":"27","author":"Vinod","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"issue":"5\u20136","key":"10.1016\/j.physbeh.2018.12.019_bb0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00008877-200509000-00005","article-title":"A role for cannabinoid CB1 receptors in mood and anxiety disorders","volume":"16","author":"Witkin","year":"2005","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.physbeh.2018.12.019_bb0225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.physbeh.2018.12.019_bb0230","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","article-title":"Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action","volume":"30","author":"Zuardi","year":"2008","journal-title":"Revista Brasil. Psiq."},{"issue":"4","key":"10.1016\/j.physbeh.2018.12.019_bb0235","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug","volume":"39","author":"Zuardi","year":"2006","journal-title":"Braz. J. Med. Biol. Res."}],"container-title":["Physiology & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938418307509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938418307509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:05:56Z","timestamp":1758477956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031938418307509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":47,"alternative-id":["S0031938418307509"],"URL":"https:\/\/doi.org\/10.1016\/j.physbeh.2018.12.019","relation":{},"ISSN":["0031-9384"],"issn-type":[{"value":"0031-9384","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of cannabidiol in males and females in two different rat models of depression","name":"articletitle","label":"Article Title"},{"value":"Physiology & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.physbeh.2018.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}